An experimental mRNA vaccine significantly reduced the risk of skin cancer recurrence and death in patients when used in combination with the immunotherapy Keytruda,  Moderna and Merck announced this month.
Skin cancer is the most commonly diagnosed cancer in the U.S., with melanoma being the most serious type.
Trial: 44 Percent of Patients Reduced Cancer Recurrence or Death
The randomized trial included 157 patients with stage III or IV melanoma who had previously undergone surgery, according to data provided by the drug manufacturers.
One group of patients was given nine doses of the experimental mRNA vaccine (mRNA-4157/V940) made by Moderna and the immunotherapy drug Keytruda, made by Merck, every three weeks for about a year. Another group was only given Keytruda….